Trials / Terminated
TerminatedNCT00966251
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- CureTech Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this pilot study is to evaluate the safety, tolerability and activity of the monoclonal antibody CT-011 administered intravenously to patients with Primary Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-011 | CT-011 |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-08-26
- Last updated
- 2012-10-23
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00966251. Inclusion in this directory is not an endorsement.